SS
ITCI

SBI Securities’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

SBI Securities’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$3.3K – 4271
2025
Q1 		$3.3K Buy
25
+15
+150% +$1.87K ﹤0.01% 2068
2024
Q4 		$835 Buy
+10
New +$822 ﹤0.01% 2689

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SBI Securities's ITCI Position: Q2 2025 in Review

SBI Securities sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 25 shares — an estimated $3.3K sold.

SBI Securities first reported a position in ITCI in Q4 2024 and held it in 2 quarters. The position peaked at $3.3K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • SBI Securities reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • SBI Securities sold 25 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $3.3K.
  • SBI Securities first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 2 quarters.
  • SBI Securities's Intra-Cellular Therapies Inc. position peaked at $3.3K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on SBI Securities's 13F filing for Q2 2025, filed 8 Aug 2025.